statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	1.077
SG - Singapore	237
CN - Cina	121
IT - Italia	87
VN - Vietnam	84
BR - Brasile	63
DE - Germania	44
GB - Regno Unito	40
AT - Austria	39
HK - Hong Kong	36
ID - Indonesia	23
FR - Francia	22
PL - Polonia	22
JP - Giappone	19
IN - India	16
CA - Canada	15
FI - Finlandia	15
TR - Turchia	14
SE - Svezia	13
RU - Federazione Russa	12
BD - Bangladesh	10
ES - Italia	10
UA - Ucraina	9
AU - Australia	8
AR - Argentina	7
NO - Norvegia	7
PK - Pakistan	7
BE - Belgio	5
CH - Svizzera	5
IQ - Iraq	5
LT - Lituania	5
MX - Messico	5
ZA - Sudafrica	5
NL - Olanda	4
MY - Malesia	3
PA - Panama	3
EC - Ecuador	2
IE - Irlanda	2
JO - Giordania	2
KG - Kirghizistan	2
NP - Nepal	2
PH - Filippine	2
PS - Palestinian Territory	2
TW - Taiwan	2
AL - Albania	1
BO - Bolivia	1
CO - Colombia	1
EE - Estonia	1
EG - Egitto	1
GR - Grecia	1
HN - Honduras	1
IL - Israele	1
KE - Kenya	1
KZ - Kazakistan	1
NZ - Nuova Zelanda	1
PY - Paraguay	1
QA - Qatar	1
SA - Arabia Saudita	1
SK - Slovacchia (Repubblica Slovacca)	1
SY - Repubblica araba siriana	1
TH - Thailandia	1
TN - Tunisia	1
TT - Trinidad e Tobago	1
UY - Uruguay	1
UZ - Uzbekistan	1
VE - Venezuela	1
Totale	2.135

Nome	#
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists	280
Safinamide differentially modulates in vivo glutamate and GABA release in the rat hippocampus and basal ganglia	264
Therapeutic potential of RGS4 blockade in movement disorders	223
Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes	211
NOP receptor ligands and Parkinson’s disease	198
6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata	156
Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models	152
Molecular and imaging prodromal markers of dopamine neuron degeneration in animal models of Parkinson’s disease: pathophysiology and clinical perspectives	147
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia	141
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats	140
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease	128
Regulator of G-Protein Signalling 4 (RGS4) negatively modulates nociceptin/orphanin FQ opioid receptor signalling: Implication for L-Dopa-induced dyskinesia	128
Totale	2.168

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	58	0	0	0	0	0	0	0	0	0	22	17	19
2021/2022	95	2	2	4	2	2	14	8	14	6	7	11	23
2022/2023	171	14	26	11	22	27	24	6	5	19	0	11	6
2023/2024	93	8	4	4	6	8	13	4	11	2	5	4	24
2024/2025	367	5	9	37	5	27	67	2	16	46	65	48	40
2025/2026	1.104	134	34	69	136	202	78	148	80	103	120	0	0
Totale													2.168

SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara